- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Evommune, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.05. | H.C. Wainwright reiterates Evommune stock rating on trial progress | 1 | Investing.com | ||
| EVOMMUNE Aktie jetzt für 0€ handeln | |||||
| 26.05. | H.C. Wainwright bestätigt Kaufempfehlung für Evommune nach Studienfortschritt | 1 | Investing.com Deutsch | ||
| 08.05. | Evommune übertrifft Verlustprognosen - Aktie legt zu | 3 | Investing.com Deutsch | ||
| 08.05. | Evommune, Inc. GAAP EPS of -$0.64 | 1 | Seeking Alpha | ||
| 07.05. | Evommune, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.04. | Evommune, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 17.04. | Evommune stock price target reaffirmed at $50 by H.C. Wainwright | 5 | Investing.com | ||
| 13.04. | Evommune, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.04. | Oppenheimer initiates Evommune stock rating at Outperform, $50 target | 4 | Investing.com | ||
| 07.04. | Evommune: Oppenheimer startet Coverage mit "Outperform" und sieht über 100 % Kurspotenzial | 4 | Investing.com Deutsch | ||
| 18.03. | H.C. Wainwright cuts Evommune stock price target on dilution | 8 | Investing.com | ||
| 18.03. | This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday | 1 | Benzinga.com | ||
| 17.03. | Clear Street initiates Evommune stock with buy rating on drug potential | 4 | Investing.com | ||
| 12.03. | Leerink reiterates Evommune stock rating after conference chat | 1 | Investing.com | ||
| 11.03. | Evommune: RBC Capital startet Coverage mit "Outperform" und sieht 100 % Kurspotenzial | 1 | Investing.com Deutsch | ||
| 11.03. | RBC Capital initiates Evommune stock with outperform rating | 1 | Investing.com | ||
| 06.03. | Evommune, Inc Loss At -$28.27 Mln In Q4 | - | RTTNews | ||
| 06.03. | Evommune, Inc. GAAP EPS of -$11.22, revenue of $13M | 1 | Seeking Alpha | ||
| 05.03. | Evommune, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ATAIBECKLEY | 3,960 | -4,35 % | Wall Street entdeckt Psychedelika - steht Emyria vor einer Neubewertung? | ||
| ROCKET PHARMACEUTICALS | 2,460 | -1,20 % | Aktien New York: Weitere Verluste - Iran-Krieg und China-News belasten | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Freitag ihre Talfahrt fortgesetzt. Der anhaltende Iran-Krieg und die weiter steigenden Ölpreise mahnen die Anleger zur Vorsicht. Auf die Stimmung drückte... ► Artikel lesen | |
| CORCEPT THERAPEUTICS | 61,46 | +0,39 % | CORCEPT THERAPEUTICS INC - 8-K, Current Report | ||
| KURA ONCOLOGY | 7,440 | -3,63 % | Kura Oncology, Inc.: Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy | - Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve... ► Artikel lesen | |
| CELCUITY | 76,50 | -3,16 % | Celcuity Inc.: Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in ... | Gedatolisib plus fulvestrant and palbociclib (the "gedatolisib-triplet") reduced the risk of disease progression or death by 50% vs. alpelisib plus fulvestrant (HR=0.50; 95% CI: 0.37-0.68; pGedatolisib... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 25,050 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 278,89 | +8,06 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| QIAGEN | 30,975 | +0,88 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Interesse der Investoren habe vor allem dem Tuberkulosetest... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,470 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | ||
| TANGO THERAPEUTICS | 21,470 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| ERASCA | 13,170 | -2,30 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,220 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 36,030 | 0,00 % | Mizuho erhöht Kursziel für Enliven Therapeutics im Vorfeld von Studiendaten | ||
| IMMUNOVANT | 31,110 | +0,61 % | H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data | ||
| SUMMIT THERAPEUTICS | 15,075 | 0,00 % | Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock |
Das Unternehmen EVOMMUNE INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 19,690 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVOMMUNE INC finden Sie auf Wallstreet Online.